This intracellularly-delivered anti-GSDMB antibody effectively and specifically reduced GSDMB functions, thus providing a novel therapeutic strategy for HER2-positive breast cancers.427 The high expression of GSDMD was associated with tumor invasion and affected tumor size and stage. The gene discussed is ERBB2; the disease is neoplasm.